Literature DB >> 31092459

Initial Experience With Radium-223 Chloride Treatment at the Kanazawa University Hospital.

Kazufumi Nakashima1, Tomoyuki Makino1, Suguru Kadomoto1, Hiroaki Iwamoto1, Hiroshi Yaegashi1, Masashi Iijima1, Shohei Kawaguchi1, Takahiro Nohara1, Kazuyoshi Shigehara1, Kouji Izumi1, Yoshifumi Kadono1, Shinro Matsuo2, Atsushi Mizokami3.   

Abstract

BACKGROUND/AIM: To evaluate our initial experience with radium-223 chloride (Ra-223).
MATERIALS AND METHODS: A total of 26 castration-resistant prostate cancer (CRPC) patients with bone metastases, treated with Ra-223 at our hospital were evaluated. This study aimed to observe adverse events (AEs) and changes in serum markers, and Bone Scan Index (BSI). Additionally, the relationship between these values and OS was investigated.
RESULTS: The observed AEs mainly included fatigue and nausea. Alkaline phosphatase (ALP) and bone-type alkaline phosphatase (BAP) levels decreased following the treatment; however, those of PSA and 1-CTP tended to increase, regardless of Ra-223 administration. Overall survival (OS) was significantly improved in cases with a baseline BSI value of <2 compared with those with a baseline BSI value of ≥2. Moreover, the decrease in BSI after administration of Ra-223 was an independent factor, significantly prolonging OS.
CONCLUSION: ALP and BAP levels and BSI values are suitable evaluation markers during treatment with Ra-223. Also, baseline BSI values and the decrease in BSI following treatment are independent factors predicting OS. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Alkaline phosphatase; Bone Scan Index; castration-resistant prostate cancer; prostate cancer; radium-223 chloride

Mesh:

Substances:

Year:  2019        PMID: 31092459     DOI: 10.21873/anticanres.13384

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Sarcopenia and Visceral Metastasis at Cabazitaxel Initiation Predict Prognosis in Patients With Castration-resistant Prostate Cancer Receiving Cabazitaxel Chemotherapy.

Authors:  Hiroaki Iwamoto; Hiroshi Kano; Takafumi Shimada; Renato Naito; Tomoyuki Makino; Suguru Kadomoto; Hiroshi Yaegashi; Kazuyoshi Shigehara; Kouji Izumi; Yoshifumi Kadono; Atsushi Mizokami
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

2.  Risk Scoring System for Ra-223 Discontinuation and Its Effect on Prognosis: A Retrospective Study.

Authors:  Hitoshi Ito; Hiroshi Yaegashi; Yoshiyuki Okada; Takafumi Shimada; Toshihide Yamaoka; Kazutoshi Okubo; Takashi Sakamoto; Atsushi Mizokami
Journal:  Cancer Diagn Progn       Date:  2021-07-03

3.  Appropriate Patient Status for Ra-223 Treatment in the Treatment Sequence for Castration-resistant Prostate Cancer.

Authors:  Hitoshi Ito; Hiroshi Yaegashi; Yoshiyuki Okada; Takafumi Shimada; Toshihide Yamaoka; Kazutoshi Okubo; Takashi Sakamoto; Atsushi Mizokami
Journal:  Cancer Diagn Progn       Date:  2022-07-03

4.  Administration of radium-223 and the prognosis in Japanese bone metastatic castration-resistant prostate cancer patients: A large database study.

Authors:  Takashi Kawahara; Yasuhide Miyoshi; Sahoko Ninomiya; Motoki Sato; Teppei Takeshima; Hisashi Hasumi; Kazuhide Makiyama; Hiroji Uemura
Journal:  Int J Urol       Date:  2022-08-17       Impact factor: 2.896

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.